Quoin Pharmaceuticals Ltd.
Last updated September 27, 2026
Organization details
- Legal name
- Quoin Pharmaceuticals Ltd.
- Former names
- Cellect Biotechnology Ltd. Cellect Biomed Ltd.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Israel
- Headquarters city
- Ashburn
- Headquarters state / province
- Virginia
- Headquarters country
- Israel
- Ticker symbol
- QNRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001671502
Board of directors
-
Anthony James Culverwell · DirectorSince 2023
-
Denise P. Carter · Director · Chief Operating OfficerSince 2023
-
Dennis Langer · DirectorSince 2023
-
Joseph Patrick Cooper · DirectorSince 2023
-
Michael Myers · Director · Chief Executive OfficerSince 2023
-
Michael T. Sember · DirectorSince 2023
-
Natalie Ee Mun Leong · DirectorSince 2023
Chief executives
Michael Myers
· Chief Executive Officer
Since January 2023
Director election results
Annual meeting of August 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.5%
-
97.7%
-
97.7%
-
97.7%
-
97.7%
-
99.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $408,606
- 5 purchases by 5 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 31, 2026 | Denise P. Carter Director, Officer (Chief Operating Officer) | Open-market purchase | +20,490 | $4.88 | $99,991 |
| Aug 31, 2026 | Anthony James Culverwell Director | Open-market purchase | +6,146 | $4.88 | $29,992 |
| Aug 31, 2026 | Lawlor Sally Bridget Officer (Chief Financial Officer) | Open-market purchase | +10,244 | $4.88 | $49,991 |
| Aug 31, 2026 | Michael Myers Director, Officer (Chief Executive Officer) | Open-market purchase | +20,490 | $4.88 | $99,991 |
| Aug 27, 2026 | Anthony James Culverwell Director | Grant or award | +31,352 | $5.15 | $161,463 |
| Aug 27, 2026 | Dennis Langer Director | Grant or award | +34,534 | $5.15 | $177,850 |
| Oct 14, 2025 | Dennis Langer Director | Open-market purchase | +15,152 | $8.49 | $128,640 |
| Dec 23, 2024 | Denise P. Carter Director, Officer (Chief Operating Officer) | Open-market purchase | +555,556 | $0.45 | $250,000 |
| Dec 23, 2024 | Michael Myers Director, Officer (Chief Executive Officer) | Open-market purchase | +555,556 | $0.45 | $250,000 |
| Dec 23, 2024 | Dunn Gordon Officer (Chief Financial Officer) | Open-market purchase | +122,221 | $0.45 | $54,999 |
| Dec 23, 2024 | Anthony James Culverwell Director | Open-market purchase | +100,000 | $0.45 | $45,000 |
| Sep 10, 2024 | Dunn Gordon Officer (Chief Financial Officer) | Open-market purchase | +10,000 | $0.91 | $9,100 |
| Sep 10, 2024 | Dunn Gordon Officer (Chief Financial Officer) | Open-market purchase | +10,000 | $0.71 | $7,100 |
| Sep 9, 2024 | Dunn Gordon Officer (Chief Financial Officer) | Open-market purchase | +856 | $0.80 | $685 |
| Sep 9, 2024 | Dunn Gordon Officer (Chief Financial Officer) | Open-market purchase | +4,000 | $0.78 | $3,120 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.